- Home
- NAUT vs RDIB Comparison
NAUT vs RDIB Comparison
Compare NAUT & RDIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAUT | RDIB |
|---|---|---|
| Founded | 2016 | 1937 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Movies/Entertainment |
| Sector | Industrials | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.0M | 256.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NAUT | RDIB |
|---|---|---|
| Price | $2.20 | $12.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 178.5K | 67.0K |
| Earning Date | 02-26-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $211,292,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 7.11 |
| 52 Week Low | $0.62 | $5.81 |
| 52 Week High | $2.54 | $17.40 |
Technical Indicators
Market Signals| Indicator | NAUT | RDIB |
|---|---|---|
| Relative Strength Index (RSI) | 54.82 | 51.41 |
| Support Level | $1.97 | $9.23 |
| Resistance Level | $2.20 | $14.10 |
| Average True Range (ATR) | 0.17 | 1.59 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 73.29 | 36.11 |
Price Performance
Historical ComparisonAbout NAUT Nautilus Biotechnolgy Inc.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
About RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.